32 results about "Neurochemistry" patented technology

The present invention relates to a neurochemical formulation comprising a supplement for improving function of neurons, improving memory and cognitive abilities, and reversing free radical damage caused by aging or neurodegenerative disease. The formulation comprises phosphoesters and antioxidants. Components may have antioxidant properties or enhance properties of other components. The synergistic combinations allow individual component dosages to be reduced, thereby minimizing potential toxicity.

A set of brain data representing a time series of neurophysiologic activity acquired by spatially distributed sensors arranged to detect neural signaling of a brain (such as by the use of magnetoencephalography) is obtained. The set of brain data is processed to obtain a dynamic brain model based on a set of statistically-independent temporal measures, such as partial cross correlations, among groupings of different time series within the set of brain data. The dynamic brain model represents interactions between neural populations of the brain occurring close in time, such as with zero lag, for example. The dynamic brain model can be analyzed to obtain the neurophysiologic assessment of the brain. Data processing techniques may be used to assess structural or neurochemical brain pathologies.

The present invention provides a method for modulating or regulating levels of a neurochemical in an individual using deep brain stimulation. More particularly, the invention relates to a method of treating neurological and psychiatric diseases by providing a feedback loop capable of maintaining central and/or peripheral nervous system neurochemical levels in an individual.

A set of brain data representing a time series of neurophysiologic activity acquired by spatially distributed sensors arranged to detect neural signaling of a brain (such as by the use of magnetoencephalography) is obtained. The set of brain data is processed to obtain a dynamic brain model based on a set of statistically-independent temporal measures, such as partial cross correlations, among groupings of different time series within the set of brain data. The dynamic brain model represents interactions between neural populations of the brain occurring close in time, such as with zero lag, for example. The dynamic brain model can be analyzed to obtain the neurophysiologic assessment of the brain. Data processing techniques may be used to assess structural or neurochemical brain pathologies.

The invention discloses a dynamic PET (polyethylene terephthalate) concentration reconstruction method based on H infinity filtration under constraint of anatomical information, comprising the following steps of: (1) obtaining anatomical information; (2) constructing a PET image reconstruction model with the constraint of anatomical information; and (3) iteratively solving by means of a H infinity filtration algorithm. The dynamic PET concentration reconstruction method based on H infinity filtration under constraint of anatomical information has the advantages that the quality of reconstructed PET image is improved by guiding PET concentration reconstruction while taking the anatomical information as space constraint, the PET image reconstruction model under constraint of anatomical information is solved by means of a H infinity filtration algorithm, the complexity of the system and the uncertainty of the system are adapted preferably, the time relevance of dynamic PET image of each frame is strengthened, the details reconstruction ability of the PET image is improved, the noise of the reconstructed image is improved, the time resolution and space resolution of the reconstructed image can be improved to a certain extent, and the method can be widely applied to the research of pharmacology and neurochemistry and other science field.

Huntington's Disease (HD) is an autosomal-dominant inherited progressive neurodegenerative disease from the group of CAG repeat/polyglutamine diseases and is characterized by a triad of psychiatric alterations, dementia and motor dysfunction. On a sub-cellular level, a mutation with extended CAG tri-nucleotide repeats has been identified as the cause of HD. The therapeutic effects of certain substances can be tested on neurotoxically-induced or transgenic animal models with expanded CAG-repeats. In the present invention, transgenic rats were generated and characterized for human HD. Said rat model for human HD and other diseases of the CNS carries 51 CAG repeats under the control of a rat promoter and has a slow progressive neurological phenotype, closely reflecting human HD syndrome. The comparability of the rat model in relation to human HD is characterized by neuropathological, neuroradiological and neurochemical modifications accompanied by typical behavioral symptoms.

A neural probe is presented for local neural optogenetics stimulation and neurochemistry recordings. The neural probe includes a probe body, a shank extending from the probe body to a tip, a plurality of micro light-emitting diodes (LEDs) positioned across a length of a first surface of the shank for providing neuron-affecting light, a plurality of carbon devices, and a plurality of carbon electrodes positioned across a length of a second surface of the shank, the second surface in opposed relation to the first surface. The plurality of carbon electrodes can be vertically aligned carbon nanotubes or vertically aligned carbon nanofibers. The plurality of carbon electrodes can also be horizontally aligned carbon nanotubes. The plurality of micro LEDs activate neurons and the plurality of vertically aligned carbon electrodes electrochemically record neurotransmitters.

A subarachnoid pharmacodialysis apparatus insertable under the scalp, in and under the cranium, with a relatively short and simple neurosurgical procedure, to be kept there safely implanted for a year or longer for the purpose of regulating the neurochemistry of one or more diseased cerebral cortical areas and thus to achieve therapeutic effects via both localized delivery of medication and drainage of local neurotoxic molecules across the subdural meninges and compartments in a feedback-controlled fashion, with or without the additional capability of performing localized neurochemistry regulation in subcortical areas. This apparatus is also used for neurochemical profiling of the diseased brain area or areas by analyzing the removed endogenous molecules and adjusting the composition of the delivered medication based on the patient's specific, abnormal neurochemistry within the treated area or areas.

The invention belongs to the technical field of analysis detection, and relates to a preparation method of a gold nanoparticle-doped molecular imprinting electrochemistry sensor for dopamine detection. The method comprises gold electrode pretreatment, gold nanoparticle self-assembly modification electrode preparation, molecular imprinting self-assembly solution preparation, electropolymerization reaction, template molecule elution and other steps so as to prepare the molecular imprinting membrane electrochemistry sensor (MIES). The method has advantages of integration of the electrochemistry sensor and the gold nanoparticle-doped imprinted polymer, can be provided for constructing the gold nanoparticle-doped molecular imprinting electrochemistry sensor for dopamine detection so as to improve selectivity of the electrochemistry sensor, provide characteristics of rapid response, good stability and good tolerance, and achieve efficient, sensitive and real-time detection of dopamine in a biological sample, and provides important significance for clinical diagnosis, pathology research, advances in biochemistry, neurochemistry development and the like.

The present invention relates to a software-based system, which may include a social networking website, implemented on a stand-alone computing device or over a network using computing devices. More specifically, the present invention relates to modifying the neurological structure or neurochemistry of a user of the system by improving mood, positivity level, or resilience level either over the Internet or on a stand-alone computing device so as to provide cognitive benefits to the user.

Electrical stimulation of specific facial and lingual nerves creates a more sustained pulsatility activity compared to stimulation of other cranial nerves. Pulsatility of arteries has intrinsic time constraints related to the time for vasodilation/constriction and time to return to baseline (TBL) after electrical stimulation which may affect the pulsatility response. Control of temporal patterning and the stimulation waveform maximizes the physiological response to cerebral pulsatility and its resulting effects on cerebral spinal fluid penetration into the brain parenchyma for a multitude of therapeutic uses including clearing misfolded proteins and/or administered pharmacological agents, diluting endogenous neurochemical concentrations within the brain, and reducing non-synaptic coupling.

The invention provides a neural signal recording method and a system integrating an in-vivo patch clamp and optical fiber records. The neural signal recording system comprises a fluorescence signal recording unit, an excitation unit, a patch clamp recording unit and a control and processing unit. The patch clamp recording unit comprises an electrophysiological digital-to-analog converter. The fluorescence signal recording unit records fluorescence signals. The patch clamp recording unit records electroneurographic signals. The fluorescence signals and the electroneurographic signals are synchronized in the electrophysiological digital-to-analog converter. The system provided by the invention can simultaneously reflect the change of membrane potential such as pulse discharge and the change condition of neurochemical signals of a related loop, and qualitatively improves dimensionality and form of neural signal records as well as richness of acquired data.

The present invention relates to the use of compounds from the group of 1-oxadibenzo[e,h]azulenes and of their pharmacologically acceptable salts and solvates in pharmaceutical formulation for the treatment and prevention of diseases, damages and disorders of the central nervous system (CNS) caused by disorders of the neurochemical equilibrium of biogenic amines or other neurotransmitters.

The invention provides an intracerebral neurochemical substance detection method which is characterized by comprising the following steps: with a carbon fiber microelectrode as a working electrode, respectively carrying out in-vitro voltammetry tests in different neurochemical substance standard solutions by virtue of a rapid scanning voltammetry method; constructing and training an artificial neural network model or loading an existing artificial neural network model for transfer learning; carrying out in-vivo in-situ analysis on a neurochemical signal by using a rapid scanning voltammetry; extracting a rapid scanning volt-ampere data current value under a characteristic potential according to electrochemical volt-ampere characteristics of a to-be-detected object; normalizing the extracted current value, and constructing a data set; and substituting the data set into the artificial neural network model, and converting a model output result into a concentration calculation value. The intracerebral neurochemical substance detection method provided by the invention can simultaneously and accurately perform quantitative analysis on various substance changes, has good anti-interferenceability, can realize long-time in-vivo in-situ recording, and has the broads application prospects.

A computer-implemented neuro-chemical and neuro-circuitry conditioning training method that employs specially programmed computing devices and systems that guides a user through a process to discover, extract, describe, and synthesize their inner dream (or dreams) and interacts with a user in order to design their dream as they have imagined it. Through the assets, environment, and other such deliverables generated from the various method modules along with specially programed computing devices, the user is enabled to interact with the assets and the generated environment and replay those interactions on-demand thereby effecting neuro-chemical and neuro-circuitry training.

The present invention relates to a method and system for using neurochemical markers to enable whether a subject is experiencing acute stress, trauma, or PTSD and providing the capacity to monitor response to therapy on an individual basis. The markers can be an increase of NAA, glutamine or Fuc IV and lactate and a decrease of Fuc IV during the transition from acute stress to PTSD.